Paper11697106
Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential.
Sekido T and 11 others. J Drug Target, 2001. Cited by 61 papers, by iCite.
Cite this record
ConductScience Library. Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential. Papers, record 11697106. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11697106
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Novel drug delivery system to bone using acidic oligopeptide: pharmacokinetic characteristics and pharmacological potential.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bone and Bones | Major topic |
| Oligopeptides | Major topic |
| Acids | |
| Animals | |
| Chromatography, High Pressure Liquid | |
| Drug Carriers | |
| Drug Delivery Systems | |
| Durapatite | |
| Estradiol | |
| Female | |
| Fluorenes | |
| Mice | |
| Osteoporosis | |
| Ovariectomy | |
| Receptors, Estrogen |
Source PubMed
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 61 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42410273 | Nanodrug delivery systems enhance traditional Chinese medicine treatment of osteoporosis. | Discov Nano | 2026 | https://conductscience.org/library/papers/42410273 | PubMed |
| 41725887 | Nanoparticles Targeting the Tumor Microenvironment for the Treatment of Osteosarcoma: Recent Progress and Perspectives. | Int J Nanomedicine | 2026 | https://conductscience.org/library/papers/41725887 | PubMed |
| 40954411 | Image-guided in vivo evaluation and comparison of bone-targeting peptides for therapeutic intervention. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/40954411 | PubMed |
| 38661537 | Advances in Bone-Targeting Drug Delivery: Emerging Strategies Using Adeno-Associated Virus. | Hum Gene Ther | 2024 | https://conductscience.org/library/papers/38661537 | PubMed |
| 38449313 | Engineering small-molecule and protein drugs for targeting bone tumors. | Mol Ther | 2024 | https://conductscience.org/library/papers/38449313 | PubMed |
| 38371454 | Bone Targeting Nanoparticles for the Treatment of Osteoporosis. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/38371454 | PubMed |
| 38056586 | Integrating osteoimmunology and nanoparticle-based drug delivery systems for enhanced fracture healing. | Nanomedicine | 2024 | https://conductscience.org/library/papers/38056586 | PubMed |
| 37198232 | Targeting strategies for bone diseases: signaling pathways and clinical studies. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37198232 | PubMed |
| 36768328 | Targeting Agents in Biomaterial-Mediated Bone Regeneration. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36768328 | PubMed |
| 36380167 | Bone-Targeted Dual Functional Lipid-coated Drug Delivery System for Osteosarcoma Therapy. | Pharm Res | 2023 | https://conductscience.org/library/papers/36380167 | PubMed |
| 35712701 | Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35712701 | PubMed |
| 35517758 | A novel biocompatible, simvastatin-loaded, bone-targeting lipid nanocarrier for treating osteoporosis more effectively. | RSC Adv | 2020 | https://conductscience.org/library/papers/35517758 | PubMed |
| 35455393 | Antiosteoporosis Effects, Pharmacokinetics, and Drug Delivery Systems of Icaritin: Advances and Prospects. | Pharmaceuticals (Basel) | 2022 | https://conductscience.org/library/papers/35455393 | PubMed |
| 35119364 | Induction of osteogenesis by bone-targeted Notch activation. | Elife | 2022 | https://conductscience.org/library/papers/35119364 | PubMed |
| 32957602 | Poly(Aspartic Acid) Functionalized Poly(ϵ-Caprolactone) Microspheres with Enhanced Hydroxyapatite Affinity as Bone Targeting Antibiotic Carriers. | Pharmaceutics | 2020 | https://conductscience.org/library/papers/32957602 | PubMed |
| 32930474 | Fluorescent Self-Threaded Peptide Probes for Biological Imaging. | Angew Chem Int Ed Engl | 2020 | https://conductscience.org/library/papers/32930474 | PubMed |
| 32860563 | Bone-Targeting Systems to Systemically Deliver Therapeutics to Bone Fractures for Accelerated Healing. | Curr Osteoporos Rep | 2020 | https://conductscience.org/library/papers/32860563 | PubMed |
| 32845464 | Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders. | Curr Osteoporos Rep | 2020 | https://conductscience.org/library/papers/32845464 | PubMed |
| 32601412 | Selection and identification of a novel bone-targeting peptide for biomedical imaging of bone. | Sci Rep | 2020 | https://conductscience.org/library/papers/32601412 | PubMed |
| 31019230 | Effect of enzyme replacement therapy on the growth of patients with Morquio A. | J Hum Genet | 2019 | https://conductscience.org/library/papers/31019230 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11697106
GET https://conductscience.org/api/papers/v1/11697106/cited_by?page=2